CMV

Cytomegalovirus (herpesvirus 5), a member of the betaherpesvirus subgroup, occurs as a benign infection in the majority of humans, with a high prevalence in the adult population. However, CMV infection continues to be a major cause of morbidity and mortality in immunosuppressed patients, especially recipients of solid organ or bone marrow transplants.

MBX-400, a novel, potent nucleoside dual DNA polymerase/kinase inhibitor, has successfully completed Phase 1 clinical development.